News

NITI Aayog Just Published India's Most Honest Assessment of Why Its Research Ecosystem Is Broken — And a Roadmap to Fix It

By Mustafa Shariff, Editor in Chief · April 20 , 2026 · 5 min

Summary

• NITI Aayog's 'Ease of Doing R&D in India' Report: The Policy Diagnosis That Every Healthcare Researcher and Biotech Founder Must Read
• NITI Aayog has released two landmark reports on India's R&D ecosystem, identifying structural barriers and recommending the ROPE framework to fix them. Here is the complete analysis and what it means for healthcare innovation.

On April 9, 2026, NITI Aayog released two comprehensive reports titled Ease of Doing Research and Development in India and the Survey Report on Ease of Doing R&D in India — the output of a nine-month consultation process involving outreach to over 400 institutional leaders and insights from more than 850 distinguished scientists and researchers across the country. Released by NITI Aayog Vice Chairman Suman Bery, with Dr Jitendra Singh, Minister of State for Science and Technology, as Chief Guest, the reports represent India's most systematic self-assessment of why its research ecosystem underperforms its human capital potential.

The central finding is both familiar and damning: India's gross expenditure on R&D remains at approximately 0.7% of GDP — well below the 2% target that has been part of national science policy for years, and less than half the global average of approximately 1.8%. But the reports go beyond the funding number to identify the institutional and administrative causes of this chronic underinvestment in a way that previous policy documents have not.

The ROPE Framework: Removing Obstacles and Promoting Enablers

NITI Aayog's analytical framework for India's R&D reform agenda is the ROPE framework — Removing Obstacles and Promoting Enablers. It identifies challenges across two dimensions: internal institutional processes (governance, procurement, funding architecture, researcher autonomy) and external ecosystem factors (regulatory systems, industry-academia linkages, private sector participation). The framework acknowledges that India's R&D problem is not primarily a shortage of scientific talent — it is a shortage of enabling conditions for that talent to produce commercially relevant output.

The Procurement Rules Destroying Indian Research

The single most damaging institutional constraint the reports identify is the application of government procurement rules — specifically the L1 (Lowest Bidder) tender requirement — to research equipment and scientific materials. Under current rules, research institutions that receive government funding must procure scientific equipment through the standard government procurement process, which mandates awarding contracts to the lowest bidder irrespective of quality, compatibility, or the specific technical requirements of the research.

The consequence is severe: a researcher in an IIT or AIIMS or a publicly funded biotech lab who needs a specific piece of analytical equipment for a drug discovery project may be compelled to purchase a cheaper, incompatible alternative because the procurement rules prohibit price-based technical discrimination. Reagents, chemical standards, and laboratory consumables — where supplier consistency is scientifically critical — are subject to the same L1 framework. The reports advocate for exempting critical scientific equipment and raw materials from rigid L1 tender rules, ensuring researchers can acquire what they actually need in days rather than months.

The Bureaucratic Culture That Kills Innovation

Beyond procurement, the reports document a broader culture of administrative overreach that stifles research productivity. Outdated institutional processes create friction at every stage: grant applications, ethics committee approvals, publication rights, IP filing, and commercialisation pathways all involve bureaucratic layers that consume researcher time and impose delays that make Indian institutions uncompetitive with international counterparts. The reports recommend a shift from an environment of administrative overreach to a trust-based, outcome-oriented ecosystem that grants researchers greater operational autonomy.

The private sector participation challenge is equally significant. India's R&D investment is overwhelmingly public-sector funded — industry contribution to R&D spending is minimal compared to countries like the US, South Korea, and Germany where industry drives the majority of R&D investment. The reports call for robust tax incentives, matching grants, and the leveraging of Corporate Social Responsibility funds directly into deep-tech startups and university incubators.

What This Means for Healthcare Research

For healthcare and pharmaceutical R&D specifically, the NITI Aayog reports connect directly to the Biopharma SHAKTI mission's ambition of creating 1,000 accredited clinical trial sites and building a world-class biotech research ecosystem. Clinical trial site accreditation requires the same administrative enabling conditions the ROPE framework addresses: functional procurement for clinical research equipment, streamlined ethics committee processes, PI autonomy over research protocols, and clear industry-academia collaboration mechanisms.

Dr Jitendra Singh's specific call for greater private sector participation through CSR initiatives is directly relevant to India's healthcare innovation ecosystem. Several of India's largest hospital groups — Apollo, Narayana, Manipal — have research arms that could become significant R&D contributors if CSR frameworks made healthcare research investment more attractive for corporate donors.

BHC Perspective

At Bengaluru Health Community, the NITI Aayog R&D report addresses the structural barriers that our own founders, mentors, and platform members navigate daily. Biotech startups trying to work with CSIR or ICMR institutions face the exact procurement and administrative friction the report documents. Clinical researchers trying to run trials in collaboration with academic medical centres face the same ethics committee delays and grant bureaucracy. The ROPE framework is the right diagnosis. The implementation will determine whether India can convert its human capital advantage into research output that changes medicine globally.

Frequently Asked Questions

Q: What are NITI Aayog's two new R&D reports?
A: NITI Aayog released 'Ease of Doing Research and Development in India' and the 'Survey Report on Ease of Doing R&D in India' on April 9, 2026 — based on nine months of consultation with 400+ institutions and 850+ scientists, identifying structural barriers to India's research productivity.

Q: What is the ROPE framework?
A: Removing Obstacles and Promoting Enablers — NITI Aayog's framework for R&D reform addressing both internal institutional barriers (procurement rules, administrative overreach, fragmented funding) and external ecosystem factors (regulatory systems, industry-academia linkages, private sector participation).

Q: What is India's R&D spending as a percentage of GDP?
A: India's gross expenditure on R&D is approximately 0.7% of GDP — well below the government's own 2% target and significantly below the global average of approximately 1.8%, driven primarily by weak private sector and industry contribution to R&D investment.